Programs
Pipeline
Underpinned by the invention of our proprietary CriPec® nanomedicines, we are developing next generation treatments for cancers and other diseases with high unmet medical needs and progressing these into the clinic.
Cristal Therapeutics is progressing a robust pipeline of nanoparticle therapeutic candidates which are rationally designed to target specific tissues, cells and intracellular components throughout the body.
Our proprietary in-house programs are focused on cancer:
CPC634
The Company’s lead candidate, CPC634, a nanoparticle containing docetaxel, is in a Phase 2 clinical study to determine its therapeutic efficacy in the treatment of patients with ovarian cancer and other solid tumours. A confirmatory trial in metastatic castration-resistant prostate cancer is planned in 2020, aiming for registration via the 505(B)(2) / Hybrid 10(3) routes in the USA and Europe respectively.
CPC634 is available for licensing.
New CriPec® product
Cristal Therapeutics is screening both marketed products and those in development to identify the active pharmaceutical ingredients (APIs) that can benefit the most from the clinical advantages of our CriPec® technology – increased tumour targeting, improved safety profile, improved PK profile, and increased solubility for injectable products.
Cristal Therapeutics has a number of ongoing partnerships and is actively looking for additional collaborations to combine the partner’s proprietary APIs with our CriPec® platform.
Our inflammation program, CPC289 is available for licensing.
CPC289
CPC289 is centred on a CriPec®-based nanoparticle that entraps dexamethasone, an approved corticosteroid therapeutic for the treatment of inflammation. In vivo proof-of-concept was achieved in two models of chronic inflammation. This exciting application of the CriPec® technology is available for licensing.
CriPec®-based nanomedicines have the following key properties:
Therapeutic outcome
- The potential to achieve improved therapeutic outcomes including superior efficacy and higher tolerability in comparison with conventional treatment modalities.
Pharmaceutical features
- Small – tuneable whilst uniform in size.
- Offer high loading and are biodegradable.
- Broad applicability – small molecules, peptides and smaller oligo.
- Excellent stability during storage, including lyophilisation.
- Fully scalable – easily manufactured to cGMP standards using a robust 2-3 step proprietary process and low-cost system.
Biological profile and Mode of Action
- Proven clinically prolonged circulation maximises accumulation at the target site.
- Customisable linkers support selectively sustained drug exposure via controlled release of native drug.
- Can be engineered to actively target defined cells, further increasing selectivity and minimising adverse effects on healthy tissues.
- Excellent safety profile of nanoparticles themselves.
© Cristal Therapeutics
Oxfordlaan 55
6229 EV Maastricht
Netherlands
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 784127.